Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report released on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Cumberland Pharmaceuticals stock opened at $1.56 on Tuesday. Cumberland Pharmaceuticals has a 1 year low of $1.43 and a 1 year high of $2.36. The firm has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.89. The company has a market cap of $22.12 million, a price-to-earnings ratio of -3.55 and a beta of 0.16. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. The firm had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several institutional investors have recently bought and sold shares of CPIX. Millennium Management LLC purchased a new stake in Cumberland Pharmaceuticals during the fourth quarter valued at about $46,000. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals during the third quarter valued at approximately $142,000. Acadian Asset Management LLC boosted its stake in Cumberland Pharmaceuticals by 27.8% in the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock valued at $529,000 after buying an additional 40,949 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Cumberland Pharmaceuticals by 6.3% in the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after purchasing an additional 38,100 shares in the last quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.